drugset / Trial / NCT06978088
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.
Timeline
- Start
- 2025-06-01
- Primary completion
- 2029-06-01
- Completion
- 2034-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | — | — |
| Subject | Rocbrutinib | Small molecule | 200 mg | — |